Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

Open in Screener

BVS

Bioventus Inc

Nov 25 • 04:00PM ET

7.79

+0.38 5.13 %

Healthcare • Medical Devices • USA • NASD

Peers: ZBH SNN GMED IART XRAY OFIX BAX CNMD PODD MEDP

| Held by: IWM VTI AVUV VXF IWO FESM SCHA VTWO DFAS IWC

Index	RUT	P/E	69.37	EPS (ttm)	0.11	Insider Own	31.30%	Shs Outstand	66.97M	Perf Week	11.44%
Market Cap	644.73M	Forward P/E	10.82	EPS next Y	0.72	Insider Trans	-0.07%	Shs Float	46.02M	Perf Month	16.10%
Enterprise Value	984.90M	PEG	3.09	EPS next Q	0.20	Inst Own	54.17%	Short Float	4.17%	Perf Quarter	4.01%
Income	7.82M	P/S	1.14	EPS this Y	9.14%	Inst Trans	0.34%	Short Ratio	5.86	Perf Half Y	19.30%
Sales	563.83M	P/B	3.14	EPS next Y	34.61%	ROA	1.06%	Short Interest	1.92M	Perf YTD	-25.81%
Book/sh	2.48	P/C	15.29	EPS next 5Y	22.47%	ROE	4.97%	52W High	12.61 -38.22%	Perf Year	-32.32%
Cash/sh	0.51	P/FCF	12.06	EPS past 3/5Y	- -113.92%	ROIC	1.59%	52W Low	5.81 34.08%	Perf 3Y	310.00%
Dividend Est.	-	EV/EBITDA	10.29	Sales past 3/5Y	9.98% 11.00%	Gross Margin	66.66%	Volatility	7.45% 5.44%	Perf 5Y	-
Dividend TTM	-	EV/Sales	1.75	EPS Y/Y TTM	118.96%	Oper. Margin	8.51%	ATR (14)	0.38	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.14	Sales Y/Y TTM	1.58%	Profit Margin	1.39%	RSI (14)	61.22	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.74	EPS Q/Q	161.98%	SMA20	8.19%	Beta	0.77	Target Price	15.00
Payout	-	Debt/Eq	2.05	Sales Q/Q	-0.23%	SMA50	11.67%	Rel Volume	0.87	Prev Close	7.41
Employees	930	LT Debt/Eq	1.96	Earnings	Nov 04 BMO	SMA200	3.94%	Avg Volume	328.02K	Price	7.79
IPO	Feb 11, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	43.27% 0.34%	Trades		Volume	285,772	Change	5.13%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-07-25	Initiated	Cantor Fitzgerald	Overweight	$12
Dec-17-24	Upgrade	JP Morgan	Underweight → Neutral	$12 → $13
Dec-07-23	Upgrade	Canaccord Genuity	Hold → Buy	$7
Aug-09-23	Upgrade	Craig Hallum	Hold → Buy	$4 → $6
Nov-22-22	Downgrade	Craig Hallum	Buy → Hold
Nov-09-22	Downgrade	JP Morgan	Overweight → Underweight
Nov-09-22	Downgrade	Canaccord Genuity	Buy → Hold	$18 → $6
Mar-15-22	Initiated	Craig Hallum	Buy	$30
Nov-15-21	Resumed	Morgan Stanley	Overweight	$20
Nov-10-21	Resumed	JP Morgan	Overweight	$25
Jul-01-21	Downgrade	Goldman	Buy → Neutral	$20 → $19
Mar-08-21	Initiated	Morgan Stanley	Overweight	$18
Mar-08-21	Initiated	JP Morgan	Overweight	$17
Mar-08-21	Initiated	Goldman	Buy	$19
Mar-08-21	Initiated	Canaccord Genuity	Buy	$23

Show Previous Ratings

Today 04:15PM	Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire) +5.13%
Nov-04-25 04:08PM	Bioventus Inc (BVS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges (GuruFocus.com) +15.09%
07:44AM	Bioventus: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Bioventus Reports Third Quarter Financial Results (GlobeNewswire)
Nov-03-25 08:02AM	What To Expect From Bioventus Inc (BVS) Q3 2025 Earnings (GuruFocus.com)
07:00AM	Loading…
Oct-28-25 07:00AM	Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025 (GlobeNewswire)
Oct-22-25 07:08PM	Halper Sadeh LLC Encourages Bioventus Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Sep-03-25 07:30AM	Bioventus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire)
Aug-13-25 12:08PM	Craig-Hallum Reiterates a Buy Rating on Bioventus (BVS), Sets a $15 PT (Insider Monkey)
Aug-07-25 04:15PM	Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference (GlobeNewswire)
Aug-06-25 08:55AM	Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates (Zacks) +18.73%
07:52AM	Bioventus: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Bioventus Reports Second Quarter Financial Results (GlobeNewswire)
Aug-05-25 10:18AM	What To Expect From Bioventus Inc (BVS) Q2 2025 Earnings (GuruFocus.com)
Aug-04-25 08:00AM	Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity (GlobeNewswire)
07:30AM	Loading…
Jul-30-25 07:30AM	Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products (GlobeNewswire)
Jul-29-25 04:15PM	Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025 (GlobeNewswire)
Jul-16-25 09:39AM	Cantor Fitzgerald Initiates Coverage of Bioventus (BVS) with an Overweight Rating (Insider Monkey)
Jun-13-25 08:30AM	Do Options Traders Know Something About Bioventus Stock We Don't? (Zacks)
May-07-25 03:09AM	Bioventus Inc (BVS) Q1 2025 Earnings Call Highlights: Navigating Growth Amidst Divestitures (GuruFocus.com) +6.29%
01:21AM	Q1 2025 Bioventus Inc Earnings Call (Thomson Reuters StreetEvents)
May-06-25 08:45AM	Bioventus (BVS) Q1 Earnings and Revenues Surpass Estimates (Zacks) -11.81%
07:50AM	Bioventus: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Bioventus Reports First Quarter Financial Results (GlobeNewswire)
May-05-25 10:10AM	Bioventus Inc (BVS) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Apr-28-25 08:00AM	Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025 (GlobeNewswire)
Apr-24-25 01:25AM	Artisan Sustainable Emerging Markets Fund Q1 2025 Commentary (Seeking Alpha)
Apr-17-25 08:21AM	4 Healthcare Stocks to Buy as the Sector Faces Government Heat (Zacks)
Apr-03-25 01:09PM	Ensign Group Invests in Growth With New Facility Acquisitions (Zacks)
Mar-31-25 09:55AM	Here's Why Bioventus (BVS) Is a Great 'Buy the Bottom' Stock Now (Zacks)
11:06AM	Loading…
Mar-28-25 11:06AM	Centene & HMHB Hawaii Expand Partnership for Maternal Care (Zacks)
Mar-17-25 12:00PM	Bioventus (BVS) Upgraded to Buy: Here's What You Should Know (Zacks)
Mar-12-25 03:08AM	Q4 2024 Bioventus Inc Earnings Call (Thomson Reuters StreetEvents) -6.76%
03:04AM	Bioventus Inc (BVS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Debt ... (GuruFocus.com)
Mar-11-25 08:45AM	Bioventus (BVS) Q4 Earnings and Revenues Surpass Estimates (Zacks) +23.29%
07:52AM	Bioventus: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-28-25 07:30AM	Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025 (GlobeNewswire)
Jan-07-25 08:00AM	Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-03-25 08:05AM	Bioventus completes divestiture of its Advanced Rehabilitation business (TipRanks)
Jan-02-25 08:00AM	Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners (GlobeNewswire)
Dec-23-24 09:40AM	Is Bioventus (BVS) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-06-24 09:55AM	Wall Street Analysts Think Bioventus (BVS) Could Surge 26.03%: Read This Before Placing a Bet (Zacks)
Nov-06-24 02:43AM	Q3 2024 Bioventus Inc Earnings Call (Thomson Reuters StreetEvents)
02:14AM	Bioventus Inc (BVS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ... (GuruFocus.com)
Nov-05-24 08:45AM	Bioventus (BVS) Matches Q3 Earnings Estimates (Zacks) -16.27%
07:41AM	Bioventus: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Bioventus Reports Third Quarter Financial Results (GlobeNewswire)
Nov-04-24 09:40AM	Are Medical Stocks Lagging Bioventus (BVS) This Year? (Zacks)
07:09AM	Bioventus Inc (BVS) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-29-24 07:30AM	Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024 (GlobeNewswire)
Oct-15-24 04:01PM	Solventum Stock Earns 81 RS Rating (Investor's Business Daily)
Oct-09-24 05:03PM	Bioventus Inc (BVS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Oct-01-24 09:00AM	Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners (GlobeNewswire)
Aug-29-24 07:09AM	Bull Of The Day: Bioventus (BVS) (Zacks)
Aug-07-24 04:15PM	Bioventus to Present at the Canaccord Genuity 44th Annual Global Growth Conference (GlobeNewswire) -7.79%
Aug-06-24 07:30AM	Bioventus Reports Second Quarter Financial Results (GlobeNewswire) +29.23%
Jul-30-24 07:30AM	Bioventus to Report Second Quarter of Fiscal Year 2024 Financial Results on August 6, 2024 (GlobeNewswire)
Jun-05-24 10:17AM	Here's Why You Should Consider Buying Bioventus (BVS) Stock (Zacks)
May-23-24 06:42AM	3 Stocks Under $10 With Mammoth Growth Prospects (InvestorPlace)
May-09-24 07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) +8.33%
May-08-24 12:28PM	Bioventus Inc. (NASDAQ:BVS) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:19AM	Bioventus Inc (BVS) Q1 2024 Earnings Call Transcript Highlights: Strong Start with Significant ... (GuruFocus.com)
May-07-24 11:41PM	Q1 2024 Bioventus Inc Earnings Call (Thomson Reuters StreetEvents) +28.00%
07:00AM	Bioventus Reports First Quarter Financial Results (GlobeNewswire)
Apr-29-24 07:30AM	Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Mar-13-24 08:48AM	Bioventus Inc. (NASDAQ:BVS) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.54%
Mar-12-24 10:20PM	Q4 2023 Bioventus Inc Earnings Call (Thomson Reuters StreetEvents) +5.46%
09:11AM	Bioventus Inc (BVS) Reports Growth in Q4 Sales and Adjusted EBITDA, Provides Optimistic 2024 ... (GuruFocus.com)
07:30AM	Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-04-24 08:00AM	Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024 (GlobeNewswire)
Jan-18-24 04:15PM	Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility (GlobeNewswire)
Jan-12-24 04:15PM	Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole (GlobeNewswire)
Dec-19-23 04:30PM	Bioventus Names Robert Claypoole as President and Chief Executive Officer (GlobeNewswire)
Dec-06-23 08:00AM	Bioventus Agrees to Nationwide Contract with Aetna Medicare Advantage Plans for DUROLANE for Knee Osteoarthritis (GlobeNewswire)
Nov-27-23 01:33AM	Smith & Nephew inks $180M CartiHeal buyout, capitalizing on Bioventus turmoil to land knee implant (MedTech Dive)
Nov-12-23 09:02AM	Bioventus Inc. (NASDAQ:BVS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 07:59AM	Bioventus Inc (BVS) Reports Q3 2023 Financial Results, Raises Full Year 2023 Financial Guidance (GuruFocus.com)
07:00AM	Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance (GlobeNewswire)
Oct-31-23 07:00AM	Bioventus to Report Third Quarter of Fiscal Year 2023 Financial Results on November 7, 2023 (GlobeNewswire) +5.37%
Oct-25-23 10:48AM	Bioventus (BVS) to Report Q3 Earnings: What's in the Cards? (Zacks)
Sep-28-23 07:43AM	3 Value Medical Stocks to Buy for Safety Amid Market Volatility (Zacks)
Sep-19-23 09:52PM	Bioventus to Present at the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-06-23 04:30PM	Bioventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-16-23 09:02AM	Juniper Investment Company, LLC Increases Stake in Bioventus Inc (GuruFocus.com) -5.26%
Aug-10-23 08:09AM	Bioventus works to trim debt under interim CEO (American City Business Journals) +11.74%
Aug-08-23 10:02PM	Q2 2023 Bioventus Inc Earnings Call (Thomson Reuters StreetEvents) +14.12% +5.41%
07:30AM	Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance (GlobeNewswire)
Aug-04-23 08:30AM	Bioventus to Present at the Canaccord Genuity 43rd Annual Global Growth Conference (GlobeNewswire)
Aug-01-23 05:35PM	Bioventus to Report Second Quarter of Fiscal Year 2023 Financial Results on August 8, 2023 (GlobeNewswire)
Jun-23-23 06:35PM	Madrigal Pharmaceuticals and Bioventus Stock See Action From Activist Investors (Barrons.com) -7.02%
May-25-23 06:38AM	Daily Vickers Top Buyers & Sellers for 05/25/2023 (Argus Research)
May-23-23 07:30AM	Bioventus Completes Divestiture of its Wound Business (GlobeNewswire) +16.27%
May-18-23 12:07PM	Bioventus Inc. (NASDAQ:BVS) Q1 2023 Earnings Call Transcript (Insider Monkey) +11.45%
May-17-23 08:33AM	Q1 2023 Bioventus Inc Earnings Call (Thomson Reuters StreetEvents) +9.17%
May-16-23 04:15PM	Bioventus Reports First Quarter Financial Results (GlobeNewswire)
May-15-23 05:33PM	Bioventus Reschedules Reporting of First Quarter Fiscal Year 2023 Financial Results to After Market Close on May 16, 2023 (GlobeNewswire)
May-11-23 07:00AM	Bioventus Reschedules Earnings Call to May 16, 2023; Files for Extension to File Form 10-Q for the Period Ended April 1, 2023 (GlobeNewswire) +17.48%
May-10-23 09:00AM	Bioventus Announces Divestiture of its Wound Business (GlobeNewswire) +6.95%
May-03-23 08:30AM	Bioventus to Report First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023 (GlobeNewswire)

Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on November 23, 2011 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McMurry-Heath Michelle	Director	Nov 07 '25	Sale	7.42	17,701	131,255	56,997	Nov 10 05:08 PM
McMurry-Heath Michelle	Director	Nov 07 '25	Proposed Sale	7.41	27,000	200,041		Nov 07 04:14 PM
Bartholdson John A.	Director	Jun 06 '25	Option Exercise	0.00	7,575	0	79,620	Jun 10 05:49 PM
Bartholdson John A.	Director	Jun 02 '25	Option Exercise	0.00	26,493	0	72,045	Jun 05 09:22 AM
SUTTER MARTIN P	Director	Jun 02 '25	Option Exercise	0.00	26,493	0	85,241	Jun 04 09:30 PM
STALNECKER SUSAN M	Director	Jun 02 '25	Option Exercise	0.00	26,493	0	105,957	Jun 04 09:30 PM
NOHRA GUY P	Director	Jun 02 '25	Option Exercise	0.00	26,493	0	126,610	Jun 04 09:30 PM
NEELS GUIDO J	Director	Jun 02 '25	Option Exercise	0.00	26,493	0	85,241	Jun 04 09:30 PM
McMurry-Heath Michelle	Director	Jun 02 '25	Option Exercise	0.00	26,493	0	74,698	Jun 04 09:30 PM
Ladone Mary Kay	Director	Jun 02 '25	Option Exercise	0.00	26,493	0	78,981	Jun 04 09:30 PM
HAWKINS WILLIAM A	Director	Jun 02 '25	Option Exercise	0.00	26,493	0	257,851	Jun 04 09:29 PM
Beyer Pat	Director	Jun 02 '25	Option Exercise	0.00	26,493	0	76,436	Jun 04 09:29 PM
Singleton Mark Leonard	SVP & CFO	Apr 11 '25	Sale	7.57	3,875	29,334	141,088	Apr 15 05:50 PM
D'Adamio Anthony	SVP & General Counsel	Apr 11 '25	Sale	7.57	2,958	22,392	131,416	Apr 15 05:50 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Apr 11 '25	Sale	7.57	1,283	9,712	55,557	Apr 15 05:49 PM
D'Adamio Anthony	Officer	Apr 11 '25	Proposed Sale	9.51	4,000	38,040		Apr 11 05:39 PM
Singleton Mark Leonard	SVP & CFO	Apr 10 '25	Option Exercise	0.00	13,000	0	144,963	Apr 11 05:31 PM
D'Adamio Anthony	SVP & General Counsel	Apr 10 '25	Option Exercise	0.00	9,925	0	134,374	Apr 11 05:30 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Apr 10 '25	Option Exercise	0.00	4,300	0	56,840	Apr 11 05:30 PM
Singleton Mark Leonard	SVP & CFO	Mar 24 '25	Sale	9.79	5,479	53,639	131,963	Mar 25 05:37 PM
Singleton Mark Leonard	Officer	Mar 24 '25	Proposed Sale	9.80	12,000	117,600		Mar 24 04:50 PM
Singleton Mark Leonard	SVP & CFO	Mar 21 '25	Option Exercise	0.00	18,625	0	137,442	Mar 21 05:24 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Mar 17 '25	Sale	9.75	1,018	9,926	52,540	Mar 18 05:34 PM
D'Adamio Anthony	SVP & General Counsel	Mar 17 '25	Sale	9.75	2,615	25,496	124,449	Mar 18 05:33 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Mar 14 '25	Option Exercise	0.00	3,456	0	53,558	Mar 14 07:06 PM
D'Adamio Anthony	SVP & General Counsel	Mar 14 '25	Option Exercise	0.00	8,886	0	127,064	Mar 14 07:05 PM
Singleton Mark Leonard	SVP & CFO	Feb 18 '25	Sale	10.19	6,498	66,215	118,817	Feb 20 07:01 PM
D'Adamio Anthony	SVP & General Counsel	Feb 18 '25	Sale	10.19	4,380	44,632	118,178	Feb 20 07:00 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Feb 18 '25	Sale	10.19	1,537	15,662	50,102	Feb 20 07:00 PM
Singleton Mark Leonard	SVP & CFO	Feb 15 '25	Option Exercise	0.00	20,153	0	125,315	Feb 18 06:00 PM
D'Adamio Anthony	SVP & General Counsel	Feb 15 '25	Option Exercise	0.00	12,980	0	122,558	Feb 18 06:00 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Feb 15 '25	Option Exercise	0.00	4,375	0	51,639	Feb 18 05:59 PM
Claypoole Robert E	President and CEO	Jan 13 '25	Sale	9.10	28,786	261,953	64,964	Jan 14 06:59 PM
Claypoole Robert E	Officer	Jan 13 '25	Proposed Sale	9.55	33,000	315,150		Jan 13 09:16 PM
Claypoole Robert E	President and CEO	Jan 10 '25	Option Exercise	0.00	93,750	0	93,750	Jan 13 05:24 PM
Singleton Mark Leonard	SVP & CFO	Dec 23 '24	Sale	10.53	10,733	113,018	105,162	Dec 26 04:55 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Dec 23 '24	Sale	10.53	2,535	26,694	47,264	Dec 26 04:55 PM
D'Adamio Anthony	SVP & General Counsel	Dec 23 '24	Sale	10.53	5,848	61,579	109,578	Dec 26 04:54 PM
Singleton Mark Leonard	Officer	Dec 23 '24	Proposed Sale	11.15	19,000	211,850		Dec 23 05:37 PM
CHURCH KATRINA J	Officer	Dec 23 '24	Proposed Sale	11.15	8,000	89,200		Dec 23 05:35 PM
D'Adamio Anthony	Officer	Dec 23 '24	Proposed Sale	11.15	16,000	178,400		Dec 23 05:34 PM
Singleton Mark Leonard	SVP & CFO	Dec 20 '24	Option Exercise	0.00	31,000	0	115,895	Dec 23 05:28 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Dec 20 '24	Option Exercise	0.00	8,600	0	49,799	Dec 23 05:28 PM
D'Adamio Anthony	SVP & General Counsel	Dec 20 '24	Option Exercise	0.00	19,850	0	115,426	Dec 23 05:27 PM

Open in Screener

RVTY

Revvity Inc

Nov 25 • 04:00PM ET

105.57

+4.99 4.96 %

Healthcare • Diagnostics & Research • USA • NYSE

Peers: TMO DHR A MTD BIO WAT BRKR ILMN

| Held by: VTI VOO VB RSP VBR IVV SPY TCAF XLV IWR

Index	S&P 500	P/E	52.79	EPS (ttm)	2.00	Insider Own	0.44%	Shs Outstand	114.03M	Perf Week	13.44%
Market Cap	11.97B	Forward P/E	19.91	EPS next Y	5.30	Insider Trans	-0.22%	Shs Float	112.88M	Perf Month	8.66%
Enterprise Value	14.41B	PEG	8.87	EPS next Q	1.54	Inst Own	103.93%	Short Float	6.80%	Perf Quarter	19.17%
Income	238.47M	P/S	4.25	EPS this Y	0.17%	Inst Trans	-0.19%	Short Ratio	5.34	Perf Half Y	15.58%
Sales	2.81B	P/B	1.63	EPS next Y	8.04%	ROA	1.87%	Short Interest	7.68M	Perf YTD	-5.41%
Book/sh	64.68	P/C	12.83	EPS next 5Y	5.95%	ROE	3.04%	52W High	128.29 -17.71%	Perf Year	-4.99%
Cash/sh	8.23	P/FCF	24.18	EPS past 3/5Y	-33.21% 3.37%	ROIC	2.35%	52W Low	81.36 29.76%	Perf 3Y	-22.47%
Dividend Est.	0.27 (0.25%)	EV/EBITDA	17.50	Sales past 3/5Y	-10.38% -0.91%	Gross Margin	48.22%	Volatility	4.04% 3.34%	Perf 5Y	-17.95%
Dividend TTM	0.28 (0.27%)	EV/Sales	5.12	EPS Y/Y TTM	-18.80%	Oper. Margin	14.78%	ATR (14)	3.26	Perf 10Y	104.71%
Dividend Ex-Date	Jan 16, 2026	Quick Ratio	1.44	Sales Y/Y TTM	3.37%	Profit Margin	8.48%	RSI (14)	71.94	Recom	2.10
Dividend Gr. 3/5Y	0.00% 0.00%	Current Ratio	1.75	EPS Q/Q	-46.77%	SMA20	12.36%	Beta	1.04	Target Price	111.20
Payout	11.63%	Debt/Eq	0.46	Sales Q/Q	2.18%	SMA50	14.56%	Rel Volume	1.43	Prev Close	100.58
Employees	11000	LT Debt/Eq	0.38	Earnings	Oct 27 BMO	SMA200	9.99%	Avg Volume	1.44M	Price	105.57
IPO	Jul 06, 1965	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.42% -0.06%	Trades		Volume	2,054,150	Change	4.96%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-25	Initiated	Guggenheim	Neutral
May-01-25	Upgrade	UBS	Neutral → Buy	$115
Jan-10-25	Downgrade	Bernstein	Outperform → Mkt Perform	$130
Dec-13-24	Upgrade	BofA Securities	Neutral → Buy	$138
Oct-15-24	Upgrade	Barclays	Equal Weight → Overweight	$125 → $140
Aug-28-24	Initiated	Wells Fargo	Equal Weight	$130
Jul-08-24	Initiated	Leerink Partners	Outperform	$125
Jun-03-24	Resumed	Jefferies	Hold	$115
Jan-16-24	Downgrade	UBS	Buy → Neutral	$105 → $125
Jan-04-24	Upgrade	Evercore ISI	In-line → Outperform	$88 → $125
Dec-19-23	Initiated	Wells Fargo	Equal Weight	$95
Dec-13-23	Initiated	Wolfe Research	Peer Perform
Sep-28-23	Initiated	Bernstein	Outperform	$133
Jul-19-23	Initiated	Raymond James	Outperform	$145
May-23-23	Resumed	Goldman	Buy	$150

Show Previous Ratings

Nov-19-25 08:35AM	Revvity Stock Outlook: Is Wall Street Bullish or Bearish? (Barchart)
Nov-10-25 07:45AM	Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities (Business Wire)
Nov-03-25 12:31AM	5 Insightful Analyst Questions From Revvity's Q3 Earnings Call (StockStory)
Oct-28-25 08:00AM	Revvity to Present at Upcoming Investor Conferences (Business Wire)
06:17AM	Company News for Oct 28, 2025 (Zacks)
01:31AM	Loading…
01:31AM	RVTY Q3 Deep Dive: AI Initiatives and Segment Divergence Shape Outlook (StockStory)
Oct-27-25 03:00PM	Revvity Inc (RVTY) Q3 2025 Earnings Call Highlights: Strong Software Growth and Strategic Share ... (GuruFocus.com)
01:22PM	Analyst Report: Revvity, Inc. (Morningstar Research)
01:10PM	Revvity (RVTY) Stock Trades Down, Here Is Why (StockStory)
10:05AM	RVTY Q3 Earnings Beat, Sales In Line, '25 EPS View Raised (Zacks)
09:30AM	Revvity (RVTY) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
07:10AM	Revvity (RVTY) Surpasses Q3 Earnings Estimates (Zacks)
06:18AM	Revvity (NYSE:RVTY) Posts Q3 Sales In Line With Estimates (StockStory)
06:09AM	Revvity: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	Revvity Announces Financial Results for the Third Quarter of 2025 (Business Wire)
11:02PM	Loading…
Oct-25-25 11:02PM	Revvity (RVTY) Q3 Earnings Report Preview: What To Look For (StockStory)
Oct-23-25 04:05PM	Revvity Board Declares Quarterly Dividend (Business Wire)
07:53AM	Will RVTY Q3 Earnings Reflect Segmental Strength Amid Rising Demand? (Zacks)
Oct-22-25 09:15AM	Revvity (RVTY) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates (Zacks)
Oct-21-25 10:00AM	Labcorp Holdings (LH) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-20-25 10:00AM	Analysts Estimate Revvity (RVTY) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-16-25 02:40AM	Here's What to Expect From Revvity's Next Earnings Report (Barchart)
Oct-14-25 11:35PM	Research Tools & Consumables Stocks Q2 Teardown: Revvity (NYSE:RVTY) Vs The Rest (StockStory)
08:00AM	Revvity Showcases Progress with Purpose in 2025 Impact Report (Business Wire)
Oct-13-25 11:38AM	Analyst Report: Revvity, Inc. (Morningstar Research)
Oct-09-25 11:55AM	RVTY Collaborates With Sanofi for Early Detection of Type 1 Diabetes (Zacks)
Oct-06-25 08:00AM	Revvity to Hold Earnings Call on Monday, October 27, 2025 (Business Wire)
Oct-02-25 08:00AM	Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes (Business Wire)
Sep-29-25 08:00AM	Revvity Unveils New AI Software Offering to Transform Preclinical Imaging Analysis (Business Wire)
Sep-23-25 02:26PM	Revvity Stock: Is RVTY Underperforming the Healthcare Sector? (Barchart)
08:00AM	Loading…
Sep-22-25 08:00AM	Revvity and Profluent Collaborate to Launch AI-Enhanced Adenine Deaminase Pin-point Base Editing Systems (Business Wire)
Sep-12-25 12:35AM	1 Oversold Stock Primed to Rebound and 2 We Brush Off (StockStory)
Sep-10-25 04:53AM	Revvity, Inc. (RVTY) Launches its New In Vivo Imaging Center of Excellence (Insider Monkey)
Sep-03-25 12:36PM	Revvity (RVTY) Stock Trades Down, Here Is Why (StockStory) -5.13%
Sep-02-25 02:26PM	Why Revvity (RVTY) Stock Is Trading Lower Today (StockStory)
08:00AM	Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina (Business Wire)
Aug-27-25 04:32PM	Bloomberg 500 (B500) Index Adds Sixteen Securities Following Semi-Annual Reconstitution (PR Newswire)
Aug-18-25 08:00AM	Revvity to Present at Upcoming Investor Conferences (Business Wire)
12:02AM	3 Reasons to Sell RVTY and 1 Stock to Buy Instead (StockStory)
Aug-13-25 12:23AM	The Top 5 Analyst Questions From Revvity's Q2 Earnings Call (StockStory)
12:21AM	RVTY Q2 Deep Dive: China Diagnostics Headwinds Offset Life Sciences Stability (StockStory)
Aug-12-25 02:20PM	Revvity, Avantor, Azenta, Bio-Techne, and Amneal Shares Skyrocket, What You Need To Know (StockStory)
Aug-06-25 08:00AM	Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics (Business Wire)
Jul-30-25 09:25AM	Revvity price target lowered to $110 from $120 at Stifel (TipRanks)
Jul-29-25 03:02AM	Revvity Inc (RVTY) Q2 2025 Earnings Call Highlights: Strong Software Growth and Strategic Share ... (GuruFocus.com)
Jul-28-25 02:15PM	Why Revvity (RVTY) Stock Is Falling Today (StockStory) -8.32%
11:51AM	Revvity Slashes Outlook As China Policy Deals Diagnostics Blow (Benzinga)
11:51AM	Analyst Report: Revvity, Inc. (Morningstar Research)
10:11AM	RVTY Posts Q2 Earnings & Sales Beat, Raises '25 Sales View (Zacks)
09:30AM	Revvity (RVTY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
07:39AM	Revvity Stock Tumbles After Earnings. What's Dragging on the Shares. (Barrons.com)
07:10AM	Revvity (RVTY) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
06:26AM	Revvity (NYSE:RVTY) Surprises With Q2 Sales (StockStory)
06:07AM	Revvity: Q2 Earnings Snapshot (Associated Press Finance)
06:00AM	Revvity Announces Financial Results for the Second Quarter of 2025 (Business Wire)
Jul-26-25 11:04PM	What To Expect From Revvity's (RVTY) Q2 Earnings (StockStory)
Jul-25-25 12:10PM	Why Revvity (RVTY) is Poised to Beat Earnings Estimates Again (Zacks)
Jul-24-25 04:05PM	Revvity Board Declares Quarterly Dividend (Business Wire)
11:11AM	Revvity Q2 Preview: Can Strong Segments Deliver an Earnings Beat? (Zacks)
Jul-23-25 09:15AM	Wall Street's Insights Into Key Metrics Ahead of Revvity (RVTY) Q2 Earnings (Zacks)
Jul-22-25 10:00AM	GeneDx Holdings Corp. (WGS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks) +5.96%
Jul-21-25 10:00AM	Revvity (RVTY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-15-25 09:22AM	Earnings Preview: What to Expect From Revvity's Report (Barchart)
Jul-13-25 11:31PM	Reflecting On Research Tools & Consumables Stocks' Q1 Earnings: Revvity (NYSE:RVTY) (StockStory)
Jul-11-25 12:03AM	3 Reasons to Sell RVTY and 1 Stock to Buy Instead (StockStory)
Jul-07-25 08:00AM	Revvity to Hold Earnings Call on Monday, July 28, 2025 (Business Wire)
Jul-03-25 12:37AM	3 Low-Volatility Stocks in the Doghouse (StockStory)
Jun-30-25 07:20AM	5 Insightful Analyst Questions From Revvity's Q1 Earnings Call (StockStory)
Jun-27-25 10:25AM	Revvity price target lowered to $110 from $116 at BofA (TipRanks)
Jun-24-25 11:13AM	Is Revvity Stock Underperforming the Dow? (Barchart)
Jun-05-25 11:31AM	Pediatrix Medical Group (MD) Down 3.1% Since Last Earnings Report: Can It Rebound? (Zacks)
Jun-02-25 08:00AM	Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows (Business Wire)
May-23-25 10:47AM	RVTY Stock Falls Despite the Latest Launch of Automated Instrument (Zacks)
May-19-25 05:00PM	AstroNova Sends Letter to Shareholders Highlighting Growth Strategy and Strength of Board (Business Wire)
08:00AM	Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing (Business Wire)
May-14-25 04:54PM	S&P 500 Gains & Losses Today: Supermicro Stock Surges After DataVolt Deal (Investopedia) -5.88%
May-06-25 12:35AM	3 S&P 500 Stocks in the Doghouse (StockStory)
May-01-25 12:40AM	1 Safe-and-Steady Stock with Exciting Potential and 2 to Avoid (StockStory)
Apr-30-25 08:00AM	Revvity to Present at Upcoming Investor Conferences (Business Wire)
Apr-29-25 05:57AM	Company News for Apr 29, 2025 (Zacks)
03:02AM	Revvity Inc (RVTY) Q1 2025 Earnings Call Highlights: Surpassing Expectations with Strong ... (GuruFocus.com)
01:20AM	Q1 2025 Revvity Inc Earnings Call (Thomson Reuters StreetEvents)
Apr-28-25 01:18PM	RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up (Zacks)
11:49AM	Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript (Seeking Alpha)
11:13AM	Analyst Report: Revvity, Inc. (Morningstar Research)
10:47AM	Biotech Firm Revvity Reports Better-Than-Expected Earnings (Investopedia)
09:30AM	Revvity (RVTY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
07:32AM	Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook (Reuters)
07:15AM	Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates (Zacks)
06:09AM	Revvity: Q1 Earnings Snapshot (Associated Press Finance)
06:06AM	Revvity (NYSE:RVTY) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations (StockStory)
06:00AM	Revvity Announces Financial Results for the First Quarter of 2025 (Business Wire)
Apr-27-25 03:01AM	Revvity (RVTY) Q1 Earnings Report Preview: What To Look For (StockStory)
Apr-25-25 12:10PM	Why Revvity (RVTY) Could Beat Earnings Estimates Again (Zacks)
08:00AM	Segmental Performance to Drive RVTY's Q1 Earnings: Is a Beat Likely? (Zacks)
Apr-24-25 04:05PM	Revvity Board Declares Quarterly Dividend (Business Wire)
07:45AM	Bretton Fund Q1 2025 Shareholder Letter (Seeking Alpha)
Apr-23-25 10:01AM	Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-21-25 10:00AM	Earnings Preview: Revvity (RVTY) Q1 Earnings Expected to Decline (Zacks)
Apr-10-25 01:31PM	Analyst Report: Revvity, Inc. (Morningstar Research) -8.21%

Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. The firm operates through the following segments: Life Sciences and Diagnostics. The Life Sciences segment delivers innovative solutions to optimize workflows, boost productivity, and accelerate drug discovery and development. The Diagnostics segment provides instruments, reagents, assay platforms, and software to healthcare and research professionals, with a focus on reproductive health, immunodiagnostics, emerging market diagnostics, and applied genomics to enhance patient outcomes. Revvity was founded on April 19, 1937 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MICHAS ALEXIS P	Director	Aug 27 '25	Sale	89.01	500	44,505	7,270	Aug 28 04:05 PM
MICHAS ALEXIS P	Officer	Aug 27 '25	Proposed Sale	88.00	500	44,000		Aug 27 03:29 PM
McMurry-Heath Michelle	Director	May 29 '25	Sale	92.17	600	55,299	4,833	May 30 04:06 PM
McMurry-Heath Michelle	Director	May 29 '25	Proposed Sale	92.17	600	55,299		May 29 02:23 PM
McMurry-Heath Michelle	Director	Feb 06 '25	Sale	119.49	1,970	235,395	3,021	Feb 07 04:05 PM
McMurry-Heath Michelle	Director	Feb 06 '25	Proposed Sale	119.49	1,970	235,395		Feb 06 03:27 PM
Goldberg Joel S	Please See Remarks	Jan 30 '25	Option Exercise	81.29	15,170	1,233,169	48,570	Jan 31 04:05 PM
Goldberg Joel S	Please See Remarks	Jan 30 '25	Sale	126.73	15,170	1,922,513	33,400	Jan 31 04:05 PM
Goldberg Joel S	Officer	Jan 30 '25	Proposed Sale	126.73	15,170	1,922,555		Jan 30 04:05 PM
Vohra Tajinder S	Please See Remarks	Jan 07 '25	Option Exercise	81.29	5,492	446,445	25,144	Jan 08 04:05 PM
Vohra Tajinder S	Please See Remarks	Jan 07 '25	Sale	116.81	5,492	641,543	19,652	Jan 08 04:05 PM
Vohra Tajinder S	Officer	Jan 07 '25	Proposed Sale	116.81	5,492	641,539		Jan 07 04:58 PM
Singh Prahlad R.	Please See Remarks	Dec 02 '24	Option Exercise	81.29	18,365	1,492,891	108,560	Dec 03 04:05 PM
Singh Prahlad R.	Please See Remarks	Dec 02 '24	Sale	116.22	18,365	2,134,366	90,195	Dec 03 04:05 PM
Singh Prahlad R.	Officer	Dec 02 '24	Proposed Sale	115.79	18,365	2,126,483		Dec 02 10:55 AM

Black Swan Sale

50% Off Elite

BVS

Bioventus Inc

RVTY

Revvity Inc

Upgrade your FINVIZ experience